Dr Zbigniew Zasłona, PhD promoted to Chief Scientific Officer – Dr Zasłona remains a member of Molecure’s Management Board Dr Adam Gołębiowski transitioning from management board position to take on role of Senior Research Fellow
Read moreWarsaw, Poland – 5 December 2022 – Molecure S.A. (“Molecure”: WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored protein
Read moreMolecure Third Quarter 2022 Pipeline Highlights and Financial Results Proprietary pipeline progressing in-line with our strategic objectives for 2022-2025 Lead proprietary candidate, OATD-01 a novel chitinase inhibitor in sarcoidosis expected to advance into a Phase II
Read moreMarta Dudek, MD, PhD, received her PhD degree in biochemistry from the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences, in collaboration with the University of Warsaw in 2012. She has worked with oncological patients
Read moreDr van der Horst has a strong track record of biotech business development having acted as lead negotiator in over 20 licensing and M&A transactions and raised over $1.3 billion through capital market transactions during his
Read moreSenior advisor, Biology & Pharmacology. Bruce is a scientific leader with over 18 years of experience in both large and small pharmaceutical organizations. While at Johnson & Johnson, Bruce served as the project leader for numerous
Read moreDr. Zbigniew Zasłona currently serves as Chief Scientific Officer at Molecure. He also manages the Department of Biology. He obtained his PhD in 2010 at the University of Giessen and the Marburg Lung Center in Germany, studying the mechanisms
Read more- Significant partnership agreement with the world-renowned International Institute of Molecular and Cell Biology in Warsaw (IIMCB) to accelerate the strategic development of OncoArendi’s small molecule RNA platform - Novel dual acting first-in-class arginase inhibitor OATD-02
Read more- Option to in-license and develop small molecule leads against a novel target for the treatment of fibrotic diseases - Strengthens pipeline and reinforces OncoArendi’s strategic focus on fibrotic diseases including idiopathic pulmonary fibrosis (IPF) 11
Read more
